Myriad Genetics grants one-time retention stock options to executives
MYGN•Myriad Genetics approved one-time stock option awards for three executives on November 6, 2026: 146,933 shares for COO Mark S. Verratti, 121,379 for CFO Benjamin R. Wheeler and 92,632 for CSO Dale Muzzey. The options vest after three years of continued service and have 10-year terms, subject to earlier termination.
1. Executive option awards
Myriad Genetics approved one-time stock option awards on November 6, 2026, under its 2026 Employee, Director and Consultant Equity Incentive Plan. COO Mark S. Verratti received options covering 146,933 shares, CFO Benjamin R. Wheeler received options covering 121,379 shares, and CSO Dale Muzzey received options covering 92,632 shares; the options vest on the grant date’s third anniversary, subject to continued service, and have 10-year terms subject to earlier termination.
